• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

A mechanistic rationale for the investigation of sodium-glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction. Letter regarding the article 'Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial'.

作者信息

Pabel Steffen, Hamdani Nazha, Sossalla Samuel

机构信息

Department of Internal Medicine II, University Medical Centre Regensburg, Regensburg, Germany.

Department of Molecular and Experimental Cardiology, Ruhr University Bochum, Bochum, Germany.

出版信息

Eur J Heart Fail. 2021 May;23(5):841. doi: 10.1002/ejhf.2091. Epub 2021 Feb 4.

DOI:10.1002/ejhf.2091
PMID:33377246
Abstract
摘要

相似文献

1
A mechanistic rationale for the investigation of sodium-glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction. Letter regarding the article 'Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial'.对射血分数保留的心力衰竭患者进行钠-葡萄糖协同转运蛋白2抑制剂研究的机制原理。关于文章“EMPEROR-Preserved试验中射血分数保留的心力衰竭患者的基线特征”的信函
Eur J Heart Fail. 2021 May;23(5):841. doi: 10.1002/ejhf.2091. Epub 2021 Feb 4.
2
Sodium-glucose co-transporter 2 inhibitors: drugs with multiple effects, but which one is relevant to heart failure with preserved ejection fraction? Letter regarding the article 'Early benefit with empagliflozin in heart failure with preserved ejection fraction: insights from the EMPEROR-Preserved trial'.钠-葡萄糖协同转运蛋白2抑制剂：具有多种作用的药物，但哪一种与射血分数保留的心力衰竭相关？关于文章《恩格列净对射血分数保留的心力衰竭的早期获益：EMPEROR-Preserved试验的见解》的信函
Eur J Heart Fail. 2022 Jul;24(7):1323-1324. doi: 10.1002/ejhf.2466. Epub 2022 Mar 9.
3
Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial.恩格列净对射血分数保留的慢性心力衰竭患者发病率和死亡率影响的评估：EMPEROR-Preserved 试验的原理和设计。
Eur J Heart Fail. 2019 Oct;21(10):1279-1287. doi: 10.1002/ejhf.1596. Epub 2019 Sep 16.
4
Sodium-glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction: reasons for optimism.射血分数保留的心力衰竭中钠-葡萄糖协同转运蛋白2抑制剂：值得乐观的理由。
Eur J Heart Fail. 2021 Aug;23(8):1250-1255. doi: 10.1002/ejhf.2279. Epub 2021 Jul 26.
5
Sodium-glucose co-transporter 2 inhibitors-the first successful treatment for heart failure with preserved ejection fraction?钠-葡萄糖协同转运蛋白2抑制剂——射血分数保留的心力衰竭的首个成功治疗方法？
Eur J Heart Fail. 2021 Aug;23(8):1256-1259. doi: 10.1002/ejhf.2108. Epub 2021 Feb 8.
6
Sodium glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction: a systematic review and meta-analysis.射血分数保留的心力衰竭中钠-葡萄糖协同转运蛋白2抑制剂：一项系统评价和荟萃分析。
Eur J Prev Cardiol. 2022 May 6;29(6):e227-e229. doi: 10.1093/eurjpc/zwab189.
7
Cardiometabolic phenotype of heart failure with preserved ejection fraction as a target of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide receptor agonists.
Cardiovasc Res. 2021 Jul 27;117(9):1992-1994. doi: 10.1093/cvr/cvaa334.
8
Pharmacology Focus: Clinical Evidence for the Use of Sodium-Glucose Co-transporter 2 Inhibitors in Heart Failure with Preserved Ejection Fraction.药理学聚焦：钠-葡萄糖协同转运蛋白2抑制剂用于射血分数保留的心力衰竭的临床证据
S D Med. 2022 Jul;75(7):328-329.
9
Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial.恩格列净对射血分数降低的慢性心力衰竭患者发病率和死亡率影响的评估：EMPEROR-Reduced 试验的原理和设计。
Eur J Heart Fail. 2019 Oct;21(10):1270-1278. doi: 10.1002/ejhf.1536. Epub 2019 Jul 16.
10
Meta-Analysis Evaluating the Cardiovascular Efficacy of Sodium-Glucose Co-Transporter-2 Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction According to Baseline Anemia.根据基线贫血情况评估钠-葡萄糖协同转运蛋白2抑制剂对射血分数降低的心力衰竭患者心血管疗效的Meta分析
Am J Cardiol. 2022 Sep 15;179:111-114. doi: 10.1016/j.amjcard.2022.06.011. Epub 2022 Jul 22.

引用本文的文献

1
Disparities in Postdischarge Ambulatory Care Follow-Up Among Medicaid Beneficiaries With Diabetes, Hospitalized for Heart Failure.糖尿病 Medicaid 受益人心力衰竭住院患者出院后门诊医疗随访的差异。
J Am Heart Assoc. 2023 Jun 20;12(12):e029094. doi: 10.1161/JAHA.122.029094. Epub 2023 Jun 7.
2
SGLT2-Inhibitors on HFpEF Patients. Role of Ejection Fraction.钠-葡萄糖协同转运蛋白 2 抑制剂在射血分数保留型心力衰竭患者中的应用。射血分数的作用。
Cardiovasc Drugs Ther. 2023 Oct;37(5):989-996. doi: 10.1007/s10557-022-07371-7. Epub 2022 Aug 3.
3
Potential Mechanisms of SGLT2 Inhibitors for the Treatment of Heart Failure With Preserved Ejection Fraction.
钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂治疗射血分数保留的心力衰竭的潜在机制
Front Physiol. 2021 Nov 5;12:752370. doi: 10.3389/fphys.2021.752370. eCollection 2021.
4
SGLT2 Inhibitors and Their Mode of Action in Heart Failure-Has the Mystery Been Unravelled?钠-葡萄糖协同转运蛋白 2 抑制剂及其在心力衰竭中的作用机制——谜团是否已被揭开？
Curr Heart Fail Rep. 2021 Oct;18(5):315-328. doi: 10.1007/s11897-021-00529-8. Epub 2021 Sep 15.